Healthcare services buyout: McKesson and CD&R pay $5.8bn for Option Care
McKesson and Clayton Dubilier & Rice acquire Option Care Health for $5.8bn, betting on infusion services at depressed valuations.
Key Takeaways
- McKesson and CD&R are buying Option Care Health for $5.8bn, targeting infusion services at valuation multiples well below historical norms.
- Healthcare services buyout activity has accelerated as buyers spot undervalued operators in sectors squeezed by reimbursement pressure and rising costs.
- This deal reflects how private equity sees opportunity in mature healthcare services where operational improvements can drive returns.
McKesson and Clayton Dubilier & Rice are paying $5.8bn to acquire Option Care Health, marking another significant healthcare services buyout at valuations far below where similar assets traded just a few years ago, according to the Financial Times.
Option Care operates infusion services, a segment of healthcare that delivers medicines and therapies directly to patients at home or in outpatient clinics rather than hospital wards. The healthcare services buyout reflects a broader trend: buyers are spotting bargains in healthcare operators that have been battered by insurance reimbursement pressure, labour shortages and rising input costs.
| Deal value | $5.8bn for Option Care Health |
|---|---|
| Buyers | McKesson Corporation and Clayton Dubilier & Rice |
| Target business | Infusion services provider |
| Market conditions | Trading below historic valuation multiples |
| Deal category | Healthcare services buyout by established buyer and PE firm |
Why valuations in healthcare services buyout deals have collapsed
Three years ago, healthcare services companies commanded price-to-earnings multiples in the mid-teens or higher. Today, healthcare services buyout opportunities come at single-digit or low-double-digit multiples, a shift that has attracted private equity and strategic buyers willing to bet on operational turnarounds.
The squeeze on these businesses has been real. Insurers have tightened reimbursement rates for home infusion and similar services. Wage inflation has hit recruitment hard in care roles. Supply chain costs remain elevated. Many operators have seen margins contract, which depresses their valuation even if their underlying business model remains sound.
McKesson, a healthcare distributor and services conglomerate, sees infusion as a natural extension of its existing portfolio. Clayton Dubilier & Rice, one of the largest private equity firms, typically targets mature, cash-generative businesses where it can apply operational discipline and cost management to unlock value. A healthcare services buyout at this valuation multiple offers exactly that profile.
The pattern driving healthcare services buyout appetite
This deal is not an outlier. Over the past 18 months, several major healthcare services buyouts have closed at valuations that would have seemed impossible during the 2021 boom. Buyers are calculating that today’s low prices compensate for the operational headwinds.
What makes this healthcare services buyout different is the credibility of the buyers. McKesson is not a financial investor hunting a quick flip. It operates healthcare infrastructure and has the scale to drive procurement savings and operational efficiencies that smaller, standalone infusion providers cannot match. This is why a healthcare services buyout by both a strategic buyer and a PE firm signals confidence that value exists at current prices.
How does a healthcare services buyout actually work to create returns?
In this kind of healthcare services buyout, the acquirer typically improves profitability through three levers. First, procurement: McKesson’s scale lets it negotiate better prices on supplies, medications and labour management systems. Second, operational standardisation: many acquired healthcare services platforms operate with redundant back-office functions that can be consolidated. Third, reimbursement optimisation: an experienced buyer can often capture revenue that smaller operators miss through better coding, compliance and contract management.
The healthcare services buyout also benefits from being a relatively defensive sector. Home infusion and outpatient services remain essential regardless of economic cycles, and demand is growing as healthcare systems push more care into lower-cost settings away from hospitals.
What a healthcare services buyout at these prices means for the sector
If this healthcare services buyout succeeds, it will validate the thesis that depressed valuations in healthcare services represent opportunity rather than terminal decline. That in turn could unlock more consolidation, as other private equity firms and strategic buyers move to acquire similar assets before prices recover.
For investors, the healthcare services buyout signals that sectors under near-term pressure can still attract sophisticated capital at the right price. For employees and patients, consolidation brings the risk of cost-cutting and service standardisation, offset by the potential for investment in technology and training that smaller operators cannot afford.
Thewealthora’s detailed guides on M&A cycles, private equity investment structures and healthcare sector dynamics explain how these deals create value and who bears the risks.
Original reporting on this healthcare services buyout: FT Markets.
More on healthcare services buyout from Thewealthora
- Institutional investors stock market dominance returns as retail traders retreat
- Trump tariffs on Canada: Maine’s logging crisis deepens
- AI trading algorithms: retail investors go automated
- US jobs data: why markets are holding their breath
Originally reported by FT Markets. Facts verified; analysis and wording are Thewealthora’s own.
Ethan Caldwell
Executive Editor, Markets
Ethan Caldwell is Executive Editor of Thewealthora's Finance Wire, the desk that carries this site's fast coverage of US equities, corporate earnings, central bank decisions and the macro calendar.
